Nuformix (LON:NFX) Releases Earnings Results

Nuformix (LON:NFX) released its quarterly earnings results on Tuesday. The company reported GBX (0.04) earnings per share for the quarter, Digital Look Earnings reports.

Nuformix Stock Performance

Shares of LON:NFX traded down GBX 0.04 during midday trading on Tuesday, hitting GBX 0.23. 116,662,734 shares of the company’s stock traded hands, compared to its average volume of 28,102,768. The firm’s fifty day moving average price is GBX 0.28 and its two-hundred day moving average price is GBX 0.21. The company has a market cap of £4.85 million, a PE ratio of -0.59 and a beta of 1.22. Nuformix has a twelve month low of GBX 0.01 and a twelve month high of GBX 0.56.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.